These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 2884877)
1. Glucagonoma syndrome. Bloom SR; Polak JM Am J Med; 1987 May; 82(5B):25-36. PubMed ID: 2884877 [TBL] [Abstract][Full Text] [Related]
2. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Altimari AF; Bhoopalam N; O'Dorsio T; Lange CL; Sandberg L; Prinz RA Surgery; 1986 Dec; 100(6):989-96. PubMed ID: 2878500 [TBL] [Abstract][Full Text] [Related]
3. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Chastain MA Am J Med Sci; 2001 May; 321(5):306-20. PubMed ID: 11370794 [TBL] [Abstract][Full Text] [Related]
5. [Glucagonoma: evolution and treatment]. Carvajal C; Azabache V; Lobos P; Ibarra A Rev Med Chil; 2002 Jun; 130(6):671-6. PubMed ID: 12194691 [TBL] [Abstract][Full Text] [Related]
6. [Necrolytic migratory erythema revealing glucagonoma without diabetes]. Marty C; Bennet A; Bayle P; Danjoux M; Lalande T; Marguery MC; Bazex J Ann Med Interne (Paris); 2003 Dec; 154(8):552-6. PubMed ID: 15037834 [TBL] [Abstract][Full Text] [Related]
7. Dermatitis, glossitis, stomatitis, cheilitis, anemia and weight loss: a classic presentation of pancreatic glucagonoma. Povoski SP; Zaman SA; Ducatman BS; McFadden DW W V Med J; 2002; 98(1):12-4. PubMed ID: 11941895 [TBL] [Abstract][Full Text] [Related]
8. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Kindmark H; Sundin A; Granberg D; Dunder K; Skogseid B; Janson ET; Welin S; Oberg K; Eriksson B Med Oncol; 2007; 24(3):330-7. PubMed ID: 17873310 [TBL] [Abstract][Full Text] [Related]
9. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Wermers RA; Fatourechi V; Wynne AG; Kvols LK; Lloyd RV Medicine (Baltimore); 1996 Mar; 75(2):53-63. PubMed ID: 8606627 [TBL] [Abstract][Full Text] [Related]
12. Cutaneous and oral changes as the only manifestations of the glucagonoma syndrome. Ditty JF; Lang PG South Med J; 1982 Feb; 75(2):222-4. PubMed ID: 6277014 [No Abstract] [Full Text] [Related]
14. Glucagonoma tumors and syndrome. Montenegro-Rodas F; Samaan NA Curr Probl Cancer; 1981 Dec; 6(6):1-54. PubMed ID: 6276079 [No Abstract] [Full Text] [Related]
15. Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma. Saavedra C; Lamarca A; Hubner RA BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31401568 [TBL] [Abstract][Full Text] [Related]
16. Necrolytic migratory erythema and glucagonoma rising from pancreatic head. Tseng HC; Liu CT; Ho JC; Lin SH Pancreatology; 2013; 13(4):455-7. PubMed ID: 23890147 [TBL] [Abstract][Full Text] [Related]
17. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. Tolliver S; Graham J; Kaffenberger BH Int J Dermatol; 2018 Jun; 57(6):642-645. PubMed ID: 29450880 [TBL] [Abstract][Full Text] [Related]
18. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. Boden G; Ryan IG; Eisenschmid BL; Shelmet JJ; Owen OE N Engl J Med; 1986 Jun; 314(26):1686-9. PubMed ID: 2872592 [No Abstract] [Full Text] [Related]